news
Genentech-Sangamo deal to advance neurodegenerative treatments
Overall, Sangamo Therapeutics will be eligible up to $1.9 billion from Genentech, which includes various milestone and royalty payments.
List view / Grid view
Genentech Inc
news
FDA approves Actemra for emergency use in hospitalised COVID-19 patients
The monoclonal antibody Actemra (tocilizumab) was approved for emergency use in hospitalised paediatric and adult COVID-19 patients based on results from four clinical trials.
article
Antibody-drug conjugates: challenges, solutions and future potential
The ability to precisely direct powerful therapeutics not only makes treatments more effective, but also prevents debilitating side effects. Here, Dave Elder and Stacey Treichler highlight the great potential of antibody-drug conjugates (ADCs) for improved treatment of oncology indications and beyond.
news
EMA accepts marketing application for Spinal Muscular Atrophy treatment
The European Medicines Agency (EMA) has accepted the marketing authorisation application for Evrysdi™ (risdiplam) as a treatment of spinal muscular atrophy (SMA).
news
FDA approves new administration route for Phesgo to treat breast cancer
The FDA has given approval to Phesgo for injection under the skin to treat HER2-positive breast cancer, meaning it can be administered at home by a healthcare professional.
news
FDA approves chronic lymphocytic leukaemia drug Venclexta
12 April 2016 | By Victoria White, Digital Content Producer
Venclexta is the first FDA-approved treatment that targets the BCL-2 protein, which supports cancer cell growth and is overexpressed in many CLL patients...
news
FDA approves Rituxan plus a steroid for use in severe forms of vasculitis
19 April 2011 | By Biogen Idec
Genentech, and Biogen Idec announced today that the FDA approved Rituxan® (rituximab)...
news
Genentech’s ECP-1 Bacterial Manufacturing Facility Named 2010 Facility of the Year Awards Overall Winner
8 November 2010 | By ISPE
ISPE, announced that Genentech’s ECP-1 Bacterial Manufacturing Facility is the overall winner...
article
Is the dream becoming reality?
28 November 2006 | By Andy Chang and Jean-Philippe Stephan Ph.D., Assay and Automation Technology department, Genentech, Inc
During the last decade, technical developments have dramatically changed the way cell-based assays could be implemented and used in research and development organisations. Although cell-based assays have moved into a modern era, cells are still grown and maintained in the same way as decades ago; i.e. manually. However, automation systems…
